Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $247.0 million.

  • Nurix Therapeutics' Cash & Equivalents rose 12451.52% to $247.0 million in Q4 2025 from the same period last year, while for Nov 2025 it was $247.0 million, marking a year-over-year increase of 12451.52%. This contributed to the annual value of $247.0 million for FY2025, which is 12451.52% up from last year.
  • Latest data reveals that Nurix Therapeutics reported Cash & Equivalents of $247.0 million as of Q4 2025, which was up 12451.52% from $78.4 million recorded in Q3 2025.
  • Nurix Therapeutics' 5-year Cash & Equivalents high stood at $247.0 million for Q4 2025, and its period low was $33.6 million during Q1 2023.
  • In the last 5 years, Nurix Therapeutics' Cash & Equivalents had a median value of $78.6 million in 2022 and averaged $91.3 million.
  • As far as peak fluctuations go, Nurix Therapeutics' Cash & Equivalents tumbled by 7793.23% in 2022, and later soared by 13412.44% in 2024.
  • Quarter analysis of 5 years shows Nurix Therapeutics' Cash & Equivalents stood at $80.5 million in 2021, then decreased by 19.91% to $64.5 million in 2022, then fell by 15.27% to $54.6 million in 2023, then surged by 101.36% to $110.0 million in 2024, then soared by 124.52% to $247.0 million in 2025.
  • Its last three reported values are $247.0 million in Q4 2025, $78.4 million for Q3 2025, and $84.3 million during Q2 2025.